AstraZeneca's lung cancer treatment met its primary endpoint in a phase 3 trial, the company said early Monday. The drug, TAGRISSO, was tested on more than 400 patients with certain types of non-small cell lung cancers as a second-line treatment, with the results compared to standard platinum-based doublet chemotherapy. AstraZeneca is trading slightly higher in pre-market trade. The stock rose 8.2% over the last three months, compared with a 3.2% rise in the S&P 500 .
Continue Reading Below
Copyright © 2016 MarketWatch, Inc.